Table 1.
Tumor xenograft growth study.
| Groupa | Number of mice/group | Dose | Miragen compounds | Route of administration | Scheduleb |
|---|---|---|---|---|---|
| A | 12 | 100 μL | PBS | i.v. | day 0, 2, 4, and 7 following enrollment into group |
| B | 12 | 1 mg/kg | Cobomarsen | i.v. | day 0, 2, 4, and 7 following enrollment into group |
| C | 3 | 100 μL | PBS | i.v. | day 0, 2, 4, and 7 following enrollment into group |
| D | 3 | 1 mg/kg | Control oligonucleotide | i.v. | day 0, 2, 4, and 7 following enrollment into group |
a
Five- to six-week-old female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, strain number 005557) mice were divided in four groups: A and B contained 12 mice each that were injected intravenously, in the tail vein, with 100 μL of the vehicle PBS or with 1 mg/kg cobomarsen, respectively. Group A served as control for group B. The C and D groups contained 3 mice each, injected intravenously either with 100 μL PBS alone or 100 μL PBS containing 1 mg/kg of the control oligonucleotide, respectively. Group C served as control for group D.
b
For the tumor growth study, the time points of intravenous injections were scheduled as described in the table.